Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

BRIEF-Progen Pharmaceuticals says to proceed with strategic acquisition of TBG Inc.

Published 16/10/2015, 03:45 pm
© Reuters.  BRIEF-Progen Pharmaceuticals says to proceed with strategic acquisition of TBG Inc.
TDL
-

Oct 16 (Reuters) - Progen Pharmaceuticals Ltd PGL.AX :

* Progen to proceed with strategic acquisition of tbg inc.

* Says signed a share sale and purchase agreement to acquire 100% of the issued capital in tbg inc (tbg)

* Agreement to acquire 100% of the issued capital in tbg inc from medigen biotechnology corporation

* Says company will issue 101.7 million new ordinary shares to medigen in consideration

* Proposed to undertake capital raising at a minimum of $0.21 per share to raise a minimum of $10 million and a maximum of $14.5 million

* Source text for Eikon ID:nASX5lJ7tY

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.